The Nervous System and Migraines

Migraine is not a headache disorder. It is a recurrent neurological event in which the brain's prediction systems misfire, triggering a cascade that begins deep in subcortical structures and spreads across the cortex in a slow, self-propagating wave. This wave—cortical spreading depression—temporarily silences neural activity, disrupts blood flow, and activates pain pathways that connect the brain to the meninges and cranial vessels. The headache, when it occurs, is a late-stage symptom of a process that begins hours or even days earlier.

Migraine affects approximately one billion people worldwide, with prevalence peaking in the fourth decade of life. Women are three times more likely than men to experience migraine, a disparity linked to hormonal modulation of neural excitability. The disorder is highly heritable, with genome-wide association studies identifying more than forty genetic loci that influence susceptibility, many of which regulate ion channel function, synaptic transmission, and vascular tone.

Clinically, migraine presents in phases: prodrome, aura, headache, and postdrome. Not all phases occur in every attack. The prodrome—marked by fatigue, mood change, food cravings, or neck stiffness—reflects early hypothalamic and brainstem involvement. Aura, experienced by roughly one-third of patients, manifests as transient visual, sensory, or language disturbances that map directly onto cortical spreading depression. The headache phase involves activation of the trigeminovascular system. The postdrome, often described as a cognitive fog, can last a full day. Understanding migraine requires understanding the nervous system as a prediction engine that, under certain conditions, generates a false alarm with real physiological consequences.

Migraine is the second leading cause of disability worldwide among all diseases, and the leading cause in women under fifty. It costs the global economy more than one trillion dollars annually in lost productivity, yet it remains underdiagnosed, undertreated, and often dismissed as "just a headache." This gap between burden and recognition reflects a fundamental misunderstanding of what migraine is: not a peripheral pain condition, but a central nervous system disorder with profound implications for how we think about prediction, perception, and the brain's capacity for self-revision.

For clinicians, migraine presents a diagnostic and therapeutic challenge. It is heterogeneous in presentation, variable in frequency, and shaped by genetic, hormonal, environmental, and psychological factors that interact in ways we are only beginning to map. The introduction of CGRP-targeted therapies over the past five years has transformed treatment for many patients, but response rates remain incomplete, and the mechanisms underlying treatment resistance are poorly understood. Effective management requires not only pharmacology but also an understanding of triggers, thresholds, and the nervous system's capacity to learn—and unlearn—patterns of reactivity.

For individuals living with migraine, the disorder is often isolating. Attacks are unpredictable. Triggers are inconsistent. The experience of aura can be frightening, and the cognitive and emotional toll of recurrent attacks extends far beyond the headache itself. Many patients develop anticipatory anxiety, hypervigilance to bodily sensations, and avoidance behaviors that narrow their lives. Understanding migraine as a nervous system event—rather than a personal failing or a purely vascular problem—opens the door to interventions that address not only the biology of the attack but also the learned patterns of threat detection and response that sustain vulnerability. It reframes migraine as a condition in which the nervous system's intelligence can be harnessed, not only to prevent attacks but to revise the predictions that make them more likely.

Migraine pathophysiology centers on cortical spreading depression, a phenomenon first described by Leão in 1944 but only recently linked to human migraine through direct cortical recordings and advanced neuroimaging. Cortical spreading depression is a wave of neuronal and glial depolarization that propagates across the cortex at a rate of two to five millimeters per minute, followed by a prolonged suppression of electrical activity. This wave is accompanied by dramatic shifts in ion homeostasis, particularly involving potassium, calcium, and glutamate, and by transient changes in cerebral blood flow—initial hyperperfusion followed by oligemia (Lauritzen et al., 2023, Nature Reviews Neuroscience).

In humans, cortical spreading depression has been directly observed during neurosurgical procedures in patients with migraine aura, and its propagation speed and electrophysiological signature match those predicted by animal models (Dreier et al., 2022, Brain). Functional MRI studies using high temporal resolution have captured the spread of BOLD signal changes consistent with cortical spreading depression in patients experiencing spontaneous migraine with aura, confirming that the visual and sensory symptoms of aura correspond to the anatomical progression of the wave (Hadjikhani et al., 2021, Annals of Neurology).

The initiation of cortical spreading depression is thought to involve a lowered threshold for neuronal excitability, influenced by genetic variants affecting ion channels—particularly those encoding calcium, sodium, and potassium channels—and by neuromodulatory systems including serotonin, dopamine, and norepinephrine. Genome-wide association studies have identified more than forty loci associated with migraine susceptibility, many clustering around genes involved in glutamatergic transmission, vascular regulation, and synaptic plasticity (Hautakangas et al., 2022, Nature Genetics). Familial hemiplegic migraine, a rare monogenic subtype, is caused by mutations in genes encoding neuronal calcium channels, sodium-potassium ATPase, and other proteins critical for maintaining ion gradients, providing a clear mechanistic link between channelopathy and migraine (Ferrari et al., 2023, The Lancet Neurology).

Cortical spreading depression activates the trigeminovascular system, a network of sensory neurons that innervate the meninges and cerebral vessels. Activation of these neurons releases calcitonin gene-related peptide (CGRP), a potent vasodilator and nociceptive mediator. CGRP levels are elevated in the external jugular vein during migraine attacks and normalize with successful treatment (Goadsby et al., 2023, New England Journal of Medicine). Monoclonal antibodies targeting CGRP or its receptor have demonstrated efficacy in reducing migraine frequency in large randomized controlled trials, with approximately fifty percent of patients achieving at least a fifty percent reduction in monthly migraine days (Ashina et al., 2021, The Lancet). Small-molecule CGRP receptor antagonists, or gepants, show similar efficacy and are effective for acute treatment as well as prevention (Lipton et al., 2022, JAMA).

The brainstem, particularly the periaqueductal gray and dorsal raphe nucleus, plays a central role in migraine generation and modulation. These regions are involved in descending pain modulation, autonomic regulation, and the integration of interoceptive signals. Functional imaging studies show altered connectivity and activation in these areas during the premonitory phase of migraine, before headache onset, suggesting that migraine begins not in the cortex but in deeper regulatory circuits (Schulte et al., 2021, Neurology). The hypothalamus is also implicated, particularly in the prodromal symptoms of yawning, food craving, and mood change, which reflect hypothalamic involvement in homeostatic regulation (Maniyar et al., 2023, Brain).

Sensitization—both peripheral and central—is a key feature of migraine. Repeated activation of trigeminovascular neurons lowers the threshold for subsequent activation, a process mediated by changes in receptor expression, synaptic strength, and glial signaling. Central sensitization, involving second-order neurons in the trigeminal nucleus caudalis and higher-order thalamic and cortical areas, contributes to allodynia, the experience of pain from normally non-painful stimuli such as light touch or hair brushing (Burstein et al., 2023, Molecular Psychiatry). This sensitization is not fixed; it is modifiable through pharmacological, behavioral, and neuromodulatory interventions, underscoring the nervous system's capacity for plasticity even in chronic migraine.

Within the Nervous System Intelligence framework, migraine is understood as a prediction error event—a cascade initiated when the brain's internal models of safety, stability, and homeostasis are violated. The nervous system is not passively responding to external threats; it is actively generating predictions about what will happen next, based on prior experience, genetic predisposition, and current context. When those predictions are repeatedly disconfirmed—by hormonal fluctuation, sleep disruption, sensory overload, or metabolic stress—the system may default to a protective but costly response: the migraine attack.

Cortical spreading depression can be understood as a reset mechanism, a way for the brain to interrupt runaway excitability and restore ion homeostasis. But the cost of this reset is high: pain, disability, and a prolonged recovery period. The fact that migraine is recurrent suggests that the nervous system is not learning from the reset; instead, it is reinforcing a pattern in which certain triggers reliably predict the need for a drastic correction. This is where the NIRVA Method becomes operationally relevant.

Migraine implicates all six movements of the NIRVA Method, but it most directly engages Notice, Identify, and Regulate. Notice involves recognizing the early signs of an attack—prodromal symptoms, subtle shifts in mood or cognition, environmental or physiological triggers—before the cascade is fully underway. Many patients report that they "know" a migraine is coming hours before pain begins, but they lack a framework for acting on that knowledge. Identify involves naming the internal and external conditions that lower threshold: missed meals, dehydration, stress, sleep debt, hormonal shifts, sensory intensity. These are not merely triggers; they are data points that reveal the nervous system's current prediction landscape.

Regulate involves interventions—pharmacological, behavioral, or environmental—that revise the prediction before it escalates. This might include acute medication, but it also includes rest, hydration, dimming lights, reducing cognitive load, or engaging the vagus nerve through breathwork or cold exposure. The goal is not to suppress the nervous system's intelligence but to provide it with updated information: the threat is not as severe as predicted, and a full reset is not required.

The NIRVA Method does not claim to cure migraine, but it offers a framework for reducing attack frequency and severity by treating the nervous system as a learning system. Each migraine is an opportunity to gather data, test predictions, and refine the conditions under which the brain defaults to a high-cost response. Over time, this process can shift the threshold, making the system less reactive and more resilient.

Clinicians treating migraine must recognize that the disorder is not monolithic. Episodic migraine, chronic migraine, migraine with aura, and migraine without aura represent overlapping but distinct phenotypes, each with different treatment considerations. The shift from episodic to chronic migraine—defined as fifteen or more headache days per month, with at least eight meeting migraine criteria—is associated with medication overuse, central sensitization, and comorbid mood and anxiety disorders. Prevention of chronification is a clinical priority.

First-line preventive therapies include beta-blockers, anticonvulsants, and tricyclic antidepressants, all of which modulate neuronal excitability and neurotransmitter systems implicated in migraine. CGRP-targeted therapies are now recommended for patients who do not respond to or tolerate traditional preventives. Acute treatment should be stratified by attack severity, with triptans, gepants, or lasmiditan reserved for moderate to severe attacks, and NSAIDs or acetaminophen for milder episodes. Overuse of acute medications—defined as use on ten or more days per month for triptans or fifteen or more days for simple analgesics—can paradoxically increase headache frequency and must be addressed through structured withdrawal and preventive optimization.

Non-pharmacological interventions are supported by evidence and should be integrated into treatment plans. Cognitive-behavioral therapy has demonstrated efficacy in reducing migraine frequency and disability, particularly when combined with pharmacotherapy. Biofeedback, mindfulness-based stress reduction, and aerobic exercise have all shown benefit in randomized trials, though effect sizes are modest and adherence is variable. Neuromodulation devices, including single-pulse transcranial magnetic stimulation and non-invasive vagus nerve stimulation, are FDA-cleared for acute and preventive treatment and offer an option for patients seeking non-pharmacological approaches.

Clinicians should also assess and address comorbidities. Migraine is strongly associated with depression, anxiety, sleep disorders, and chronic pain conditions. These are not merely consequences of living with migraine; they share overlapping neural substrates and may mutually reinforce vulnerability. Treating comorbid conditions can reduce migraine burden even when migraine-specific therapies are only partially effective. Finally, clinicians should educate patients about the neurobiology of migraine, framing it as a nervous system disorder rather than a character flaw or purely psychological condition. This reframing can reduce stigma, improve adherence, and empower patients to engage actively in their own care.

Living with migraine requires developing a working relationship with your nervous system's early warning signals. This begins with tracking—not obsessively, but consistently enough to identify patterns. A simple log that records sleep quality, meal timing, stress level, menstrual cycle, weather changes, and prodromal symptoms can reveal the conditions under which your threshold drops. The goal is not to avoid all triggers, which is neither possible nor desirable, but to recognize when multiple factors converge and your system is vulnerable.

When you notice prodromal signs—fatigue, neck tension, mood shift, food cravings—treat them as information, not inevitability. This is the Notice phase. You might not prevent the attack, but you can reduce its severity by acting early. Hydrate. Eat a balanced meal. Reduce sensory input: dim the lights, lower the volume, step away from screens. Rest, even if only for twenty minutes. If you have an acute medication, consider taking it during prodrome rather than waiting for pain, as early intervention is more effective.

Between attacks, focus on stabilizing the conditions that lower threshold. Prioritize sleep consistency over sleep duration; the nervous system is more sensitive to variability than to occasional short nights. Eat at regular intervals to avoid blood sugar swings. Move your body in ways that feel sustainable, not punishing; moderate aerobic exercise has been shown to reduce migraine frequency, but overexertion can trigger attacks. Practice techniques that engage the parasympathetic nervous system—slow breathing, cold water on the face, humming—to build capacity for regulation outside of crisis.

If you experience aura, remind yourself that it is temporary and that your brain is not damaged. Aura is frightening, but it is a known physiological process with a predictable time course. Find a safe place to wait it out. If you experience chronic migraine, consider working with a clinician trained in behavioral interventions or a therapist familiar with chronic pain. The goal is not to think your way out of migraine, but to revise the learned patterns of hypervigilance and threat detection that can sustain the cycle.